Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612662 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02612662 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT02612662, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses
Interventions
- DRUG Placebo
- DRUG AZD4076
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-11-24 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612662
The ClinicalTrials.gov registry entry for NCT02612662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02612662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02612662 about?
NCT02612662 is a clinical study titled "A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects". This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses
What is the current status of trial NCT02612662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-11-24. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT02612662?
The interventions under investigation include: Placebo (DRUG), AZD4076 (DRUG).
Who is sponsoring clinical trial NCT02612662?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.